Efficacy, tolerability and cost effectiveness of zotepine versus olanzapine in patients of acute schizophrenia

Saroj Kothari, Poonam Patel, Mukesh Changulani, Atul Agrawal

Abstract


Background: Schizophrenia is a functional psychosis with severe personality changes and thought disorders without cerebral damage. No reports are available in literature regarding efficacy and tolerability of atypical antipsychotic drug zotepine over olanzapine a preferred drug worldwide for the treatment of schizophrenia. Therefore, present study is undertaken to evaluate efficacy, tolerability and cost effectiveness of zotepine over olanzapine in patients suffering from schizophrenia.

Methods: A prospective, randomized, single blind, parallel, 6 weeks clinical study was conducted on a total of 112 patients, of schizophrenia attending psychiatry outpatient department at G. R. Medical College, Gwalior, India randomized into two groups (56 in each). Patients received either olanzapine (10-20mg) or zotepine (75-150mg) per day for a period of 6 week. Efficacy was measured by Positive and Negative Syndrome Scale (PANSS) and Clinical Global Impression (CGI) scale whereas tolerability was measured by dropout rate and frequency of adverse effects. Cost effectiveness was calculated in terms of cost incurred for improvement at the end of treatment period.

Results: Both the drugs showed significant (P<0.05) improvement in PANSS total score as compared to their respective baseline scores however, there was no significant difference between the two groups (P>.0.05). Olanzapine showed significantly better (P<0.05) positive subscale and CGI scale score improvement as well as response rate when compared to zotepine. Incidences of adverse effects like weight gain, somnolence and hyperglycemia were 42, 32 and12 % respectively with olanzapine and 39, 30 and 9% respectively with zotepine with no significant difference (P>0.05) between the two groups. Incidence of akathisia and drop out (16% and 23%) with zotepine were significant (P<0.05) as compared to olanzapine (2% and 11%) respectively.

Conclusions: Though the efficacy of both the drugs is comparable, olanzapine appears to have better tolerability and cost effectiveness than zotepine in patients of schizophrenia.


Keywords


Efficacy, Olanzapine, Schizophrenia, Tolerability, Zotepine

Full Text:

PDF

References


Sharma HL, Sharma KK. Principles of Pharmacology; Antipsychotic Drugs. First edition, Paras medical publishing. 2007; 35: 459.

Adamou M. Community Service Models for Schizophrenia: Evidence-Based Implications and Future Directions. Psychiatry 2005; 2(2): 24-30.

Andreasen NC, Olsen S. Negative v positive schizophrenia. Definition and validation. Arch Gen Psychiatry 1982; 39:789-94.

Baptista T, De Mendoza S, Beaulieu S, Bermudez A, Martinez M. The metabolic syndrome during atypical antipsychotic drug treatment: mechanisms and management. Metab Syndr Relat Disord 2004; 2(4): 290-307.

Gao K, Ganocy SJ, Gajwani P, Muzina DJ, Kemp DE, Calabrese JR. A review of sensitivity and tolerability of antipsychotics in patients with bipolar disorder or schizophrenia: focus on somnolence. J Clin Psychiatry 2008; 69(2): 302-9.

Kumar R, Sachdev PS. Akathisia and second generation antipsychotic drugs. Current opinion in psychiatry 2009; 22 (3):293-99.

Kane JM, Barrett EJ, Casey DE, Correll CU, Gelenberg AJ, Klein S, et al. Metabolic effects of treatment with atypical antipsychotics. J Clin Psychiatry 2004; 65(11): 1447-55.

Petit M, Raniwalla J, Tweed J, Leutenegger E, Dollfus S, Kelly F. A comparison of an atypical and typical antipsychotic, zotepine versus haloperidol in patients with acute exacerbation of schizophrenia: a parallel-group double-blind trial. Psychopharmacol Bull. 1996; 32:81-7.

Cooper SJ, Tweed J, Raniwalla J, Butler A, Welch C. A placebo-controlled comparison of zotepine versus chlorpromazine in patients with acute exacerbation of schizophrenia. Acta Psychiatr Scand 2000; 101(3): 218-25.

American Psychiatric Association: Diagnostic and statistical manual of mental disorders: DSM IV-TR American psychiatric publishing 2000.

Kay S, Opler L, Lindenmayer J. The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation. Br J Psychiatry 1989; 155 (suppl. 7):59 -67.

Haro JM, Kamath SA, Ochoa S, Novick D, Rele K, Fargas A, et al. The Clinical Global Impression-Schizophrenia Scale: A simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr Scand. 2003; (416):16-23.

Simpson GM, Angus JWS: A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica 1970; 212:11-19.

Barnes TRE: A Rating Scale for Drug-Induced Akathisia. Br J Psychiatry 1989; 154: 672-76.

Granata AV, Hillman AL. Competing practice guidelines: using cost-effectiveness analysis to make optimal decisions. Ann Intern Med 1998; 128: 56-63.

Franz M, Ranger J, Hanewald B, Gallhofer B, Lay B. Influences on therapist's decisions for neuroleptic treatment in schizophrenia: the role of characteristics of the patient and the physician. Pharmacopsychiatry 2012; 45(7):261-8.

Sanger TM, Lieberman JA, Tohen M, Starr Grundy PH, Beasley C, and Tollefson GD. Olanzapine versus Haloperidol Treatment in First-Episode Psychosis Am J Psychiatry 1999; 156(1): 79-87.

Hwang TJ, Lin SK and Lin HN. Efficacy and safety of zotepine for the treatment of Taiwanese schizophrenic patients: a double-blind comparison with haloperidol. J Formos Med Assoc 2001; 100: (12) 811-16.

Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW, Beasley CB et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997; 17: 407-18.

Fleischhacker WW, McQuade RD, Marcus RN, Archibald D, Swanink R, Carson WH. A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia. Biol Psychiatry 2009; 65(6): 510-17.

Josse E, Paul MFA, Alan S, Walter HML, Anton AHP. Interaction of antipsychotic drug with neurotransmitter receptor site in vitro and in vivo in relation to pharmacological and clinical effects: role of 5HT2 receptors. Psychopharmacology 1993; 112:S40-S55.

Tatsumia M, Jansena K, Blakelyc RD, Richelson E. Pharmacological profile of neuroleptics at human monoamine transporters. Eur J Pharmacol 1999;368(2-3):277-83.

Simpson GM, Weiden P, Pigott T, Murray S, Siu CO, Romano SJ. Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia. Am J Psychiatry 2005; 162(8):1535-8.

Albaugh VL, Vary TC, Ilkayeva O, Wener BR, Maresca KP, Joyal JL, et al. Atypical Antipsychotics Rapidly and Inappropriately Switch Peripheral Fuel Utilization to Lipids, Impairing Metabolic Flexibility in Rodents. Schizophrenia Bulletin 2010; 38 (1):153-66.

Weston-Green KL, Huang XF, Deng C. Alterations to melanocortinergic, GABAergic and cannabinoid neurotransmission associated with olanzapine-induced weight gain. PloS one 2012; 7(3): e33548.

Kirk SL, Glazebrook J, Grayson B, Neill JC, Reynolds GP. Olanzapine induced weight gain in the rat: role of 5-HT2C and histamine H1 receptors. Psychopharmacology2009;207:119-25 .

Weston-Green K, Huang XF, Lian J, Deng C. Effects of olanzapine on muscarinic M3 receptor binding density in the brain relates to weight gain, plasma insulin and metabolic hormone levels. Eur Neuropsychopharmacol 2012;22(5):364-73.

Piparva KG, Buch JG, Chandrani KV. Analysis of Adverse Drug Reactions of Atypical Antipsychotic Drugs in Psychiatry OPD. Indian J Psychol Med 2011;33(2):153-7.

Catalano G, Grace JW, Catalano MC, Morales MJ, Cruse LM. Acute akathisia associated with quetiapine use. Psychosomatics 2005;46:291-301.

Kirsch P, Ronshausen S, Mier D, Gallhofer B. The influence of antipsychotic treatment on brain reward system reactivity in schizophrenia patients. Pharmacopsychiatry 2007;40(5):196-8.